Roivant Sciences is trading at $34.88, up 4.59%, with the catalyst for the pre-market move unclear. - No verified overnight company announcement or report directly explains the rise. - Citi recently placed Roivant Sciences on an upside 90-day catalyst watch, citing upcoming Phase 3 data for brepocitinib; the note is not established as the cause of this move. - Supplied market context is mixed and does not clearly account for the gain.